Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer

Ichiro Nagata,1,2 Takashi Ogino,1 Takeshi Arimura,1 Takashi Yoshiura2 1Medipolis Proton Therapy and Research Center, Ibusuki, Kagoshima, Japan; 2Department of Radiology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, JapanCorrespondence: Ichiro NagataMedipolis Proto...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nagata I, Ogino T, Arimura T, Yoshiura T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	proton therapy carcinoma non-small-cell lung ground-glass opacity adenocarcinoma japan Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8ca552fdc24046b8ae9aaf5383448536
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8ca552fdc24046b8ae9aaf5383448536
record_format	dspace
spelling	oai:doaj.org-article:8ca552fdc24046b8ae9aaf53834485362021-12-02T11:20:57ZClinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer1179-2728https://doaj.org/article/8ca552fdc24046b8ae9aaf53834485362020-10-01T00:00:00Zhttps://www.dovepress.com/clinical-outcomes-of-proton-beam-therapy-for-ground-glass-opacity-type-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Ichiro Nagata,1,2 Takashi Ogino,1 Takeshi Arimura,1 Takashi Yoshiura2 1Medipolis Proton Therapy and Research Center, Ibusuki, Kagoshima, Japan; 2Department of Radiology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, JapanCorrespondence: Ichiro NagataMedipolis Proton Therapy and Research Center, 4423 Higashikata, Ibusuki, Kagoshima 891-0304, JapanTel +81 993 23 5188Fax +81 993 24 3450Email nagata-ichiro@snbl.co.jpPurpose: Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC), including ground-glass opacity (GGO)-type lung cancer. However, some patients are inoperable or refuse to undergo surgery. To explore whether proton beam therapy (PBT) can be an alternative to surgical resection in these patients, this study aimed to examine the retrospective treatment outcomes of patients with GGO-type lung cancer who underwent PBT.Patients and Methods: Patients with stage I NSCLC and GGOs who underwent PBT at the Medipolis Proton Therapy and Research Center (Kagoshima, Japan) between April 2011 and September 2015 were included. Patients were treated with a total dose of 66 GyE delivered in 10 fractions. Survival curves were calculated using the Kaplan–Meier method, and treatment-related adverse events (AEs) were assessed.Results: A total of 48 patients (median age: 70.9 ± 9.2 years; men: 54.2%) were analyzed, among whom 53 tumors were observed. The 3-year overall survival rate after PBT was 91.7% (95% confidence interval [CI], 79.3– 96.8%), the 3-year disease-free survival rate was 85.4% (95% CI: 71.8– 92.8%), and the 3-year local control rate among 53 tumors was 92.5% (95% CI: 81.1– 97.1%). During the 3-year follow-up period, 4 patients died, and 3 survived despite recurrence or metastasis. Common AEs were radiation pneumonitis (89.6%), rib fracture (27.1%), and cough (27.1%). None of the patients developed grade ≥ 3 treatment-related AEs.Conclusion: The results of this study suggest that PBT may be a promising alternative for patients with GGO-type lung cancer when surgical resection is not feasible, with excellent survival outcomes and tolerable treatment-related AEs.Keywords: proton therapy, carcinoma, non-small-cell lung, ground-glass opacity, adenocarcinoma, JapanNagata IOgino TArimura TYoshiura TDove Medical Pressarticleproton therapycarcinomanon-small-cell lungground-glass opacityadenocarcinomajapanNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 11, Pp 105-111 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	proton therapy carcinoma non-small-cell lung ground-glass opacity adenocarcinoma japan Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	proton therapy carcinoma non-small-cell lung ground-glass opacity adenocarcinoma japan Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Nagata I Ogino T Arimura T Yoshiura T Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
description	Ichiro Nagata,1,2 Takashi Ogino,1 Takeshi Arimura,1 Takashi Yoshiura2 1Medipolis Proton Therapy and Research Center, Ibusuki, Kagoshima, Japan; 2Department of Radiology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, JapanCorrespondence: Ichiro NagataMedipolis Proton Therapy and Research Center, 4423 Higashikata, Ibusuki, Kagoshima 891-0304, JapanTel +81 993 23 5188Fax +81 993 24 3450Email nagata-ichiro@snbl.co.jpPurpose: Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC), including ground-glass opacity (GGO)-type lung cancer. However, some patients are inoperable or refuse to undergo surgery. To explore whether proton beam therapy (PBT) can be an alternative to surgical resection in these patients, this study aimed to examine the retrospective treatment outcomes of patients with GGO-type lung cancer who underwent PBT.Patients and Methods: Patients with stage I NSCLC and GGOs who underwent PBT at the Medipolis Proton Therapy and Research Center (Kagoshima, Japan) between April 2011 and September 2015 were included. Patients were treated with a total dose of 66 GyE delivered in 10 fractions. Survival curves were calculated using the Kaplan–Meier method, and treatment-related adverse events (AEs) were assessed.Results: A total of 48 patients (median age: 70.9 ± 9.2 years; men: 54.2%) were analyzed, among whom 53 tumors were observed. The 3-year overall survival rate after PBT was 91.7% (95% confidence interval [CI], 79.3– 96.8%), the 3-year disease-free survival rate was 85.4% (95% CI: 71.8– 92.8%), and the 3-year local control rate among 53 tumors was 92.5% (95% CI: 81.1– 97.1%). During the 3-year follow-up period, 4 patients died, and 3 survived despite recurrence or metastasis. Common AEs were radiation pneumonitis (89.6%), rib fracture (27.1%), and cough (27.1%). None of the patients developed grade ≥ 3 treatment-related AEs.Conclusion: The results of this study suggest that PBT may be a promising alternative for patients with GGO-type lung cancer when surgical resection is not feasible, with excellent survival outcomes and tolerable treatment-related AEs.Keywords: proton therapy, carcinoma, non-small-cell lung, ground-glass opacity, adenocarcinoma, Japan
format	article
author	Nagata I Ogino T Arimura T Yoshiura T
author_facet	Nagata I Ogino T Arimura T Yoshiura T
author_sort	Nagata I
title	Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
title_short	Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
title_full	Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
title_fullStr	Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
title_full_unstemmed	Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
title_sort	clinical outcomes of proton beam therapy for ground-glass opacity-type lung cancer
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/8ca552fdc24046b8ae9aaf5383448536
work_keys_str_mv	AT nagatai clinicaloutcomesofprotonbeamtherapyforgroundglassopacitytypelungcancer AT oginot clinicaloutcomesofprotonbeamtherapyforgroundglassopacitytypelungcancer AT arimurat clinicaloutcomesofprotonbeamtherapyforgroundglassopacitytypelungcancer AT yoshiurat clinicaloutcomesofprotonbeamtherapyforgroundglassopacitytypelungcancer
_version_	1718395997299671040

Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer

Ejemplares similares